Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease

Venkateswaran, Nandini; Bian, Yandong; Gupta, Preeya K.

doi:10.2147/opth.s323301

Cited by 11 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An alternative method to prolong the ocular residence time has been devised by formulating mucus-penetrating nanoparticles. This technology involves specific nanocarriers designed with an engineering coating that prevents adherence to mucins and allows effective mucus penetration [ 139 ]. This approach was utilized to produce 0.25% loteprednol etabonate nanoparticles coated with Poloxamer 407, marketed as Eysuvis ® (KPI-121 0.25%), which received FDA approval in 2020 for the short-term (up to two weeks) treatment of DED [ 70 ].…”

Section: Nanotechnologies Currently Approved For Dry Eye Diseasementioning

confidence: 99%

Recent Advances in Nanotechnology for the Treatment of Dry Eye Disease

Coco,

Buffon,

Taloni

et al. 2024

Nanomaterials

View full text Add to dashboard Cite

Dry eye disease (DED) incidence is continuously growing, positioning it to become an emergent health issue over the next few years. Several topical treatments are commonly used to treat DED; however, reports indicate that only a minor proportion of drug bioavailability is achieved by the majority of eye drops available on the market. In this context, enhancing drug ability to overcome ocular barriers and prolonging its residence time on the ocular surface represent a new challenge in the field of ocular carrier systems. Therefore, research has focused on the development of multi-functional nanosystems, such as nanoemulsions, liposomes, dendrimers, hydrogels, and other nanosized carriers. These systems are designed to improve topical drug bioavailability and efficacy and, at the same time, require fewer daily administrations, with potentially reduced side effects. This review summarizes the different nanotechnologies developed, their role in DED, and the nanotechnology-based eyedrops currently approved for DED treatment.

show abstract

Section: Nanotechnologies Currently Approved For Dry Eye Diseasementioning

confidence: 99%

Recent Advances in Nanotechnology for the Treatment of Dry Eye Disease

Coco,

Buffon,

Taloni

et al. 2024

Nanomaterials

View full text Add to dashboard Cite

show abstract

“…In clinical trials, lifitegrast 5% improved both eye dryness scores and ocular surface signs, including tear production and corneal staining, from baseline compared to vehicle [ 20 – 22 ]. In terms of available short-term treatment (up to 2 weeks) options, loteprednol etabonate is a topical anti-inflammatory corticosteroid indicated for dry eye flares [ 23 ]. Loteprednol etabonate ophthalmic suspension 0.25% was evaluated in clinical trials involving adult participants with ocular discomfort (based on Symptom Assessment in Dry Eye [SANDE]) and signs (non-anesthetized Schirmer tear test [STT], corneal staining, and conjunctival hyperemia) and was found to improve ocular discomfort severity and conjunctival hyperemia compared to vehicle [ 23 , 24 ] (Table 1 ).…”

Section: Dry Eye Disease Sourcesmentioning

confidence: 99%

“…In terms of available short-term treatment (up to 2 weeks) options, loteprednol etabonate is a topical anti-inflammatory corticosteroid indicated for dry eye flares [ 23 ]. Loteprednol etabonate ophthalmic suspension 0.25% was evaluated in clinical trials involving adult participants with ocular discomfort (based on Symptom Assessment in Dry Eye [SANDE]) and signs (non-anesthetized Schirmer tear test [STT], corneal staining, and conjunctival hyperemia) and was found to improve ocular discomfort severity and conjunctival hyperemia compared to vehicle [ 23 , 24 ] (Table 1 ). Beyond the abovementioned products, several compounds are currently under investigation or have been recently approved and will be discussed below.…”

Section: Dry Eye Disease Sourcesmentioning

confidence: 99%

Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease

Valdés-Arias,

Locatelli,

Sepulveda-Beltran

et al. 2024

Drugs

View full text Add to dashboard Cite

Dry eye disease (DED) can arise from a variety of factors, including inflammation, meibomian gland dysfunction (MGD), and neurosensory abnormalities. Individuals with DED may exhibit a range of clinical signs, including tear instability, reduced tear production, and epithelial disruption, that are driven by different pathophysiological contributors. Those affected often report a spectrum of pain and visual symptoms that can impact physical and mental aspects of health, placing an overall burden on an individual’s well-being. This cumulative impact of DED on an individual’s activities and on society underscores the importance of finding diverse and effective management strategies. Such management strategies necessitate an understanding of the underlying pathophysiological mechanisms that contribute to DED in the individual patient. Presently, the majority of approved therapies for DED address T cell-mediated inflammation, with their tolerability and effectiveness varying across different studies. However, there is an emergence of treatments that target additional aspects of the disease, including novel inflammatory pathways, abnormalities of the eyelid margin, and neuronal function. These developments may allow for a more nuanced and precise management strategy for DED. This review highlights the recent pharmacological advancements in DED therapy in the United States. It discusses the mechanisms of action of these new treatments, presents key findings from clinical trials, discusses their current stage of development, and explores their potential applicability to different sub-types of DED. By providing a comprehensive overview of products in development, this review aims to contribute valuable insights to the ongoing efforts in enhancing the therapeutic options available to individuals suffering from DED.

show abstract

“…94 Ocular lubricants come in a variety of formulations, some of which have lipids to supplement the lipid layer of the tear film, 95 and some of which are preservative-free. 96 Topical anti-inflammatory treatments include corticosteroids (for short-term treatment, as long-term use is associated with numerous complications 97 ), cyclosporine A, and lifitegrast. 97 For patients with evaporative DED related to meibomian gland dysfunction, topical or oral antibiotics may be considered as well as procedures such as therapeutic meibomian gland expression, thermal pulsation, intraductal probing, and intense pulsed light.…”

Section: Clinical Perspective: Managing Dry Eye Disease In Patients W...mentioning

confidence: 99%

“…96 Topical anti-inflammatory treatments include corticosteroids (for short-term treatment, as long-term use is associated with numerous complications 97 ), cyclosporine A, and lifitegrast. 97 For patients with evaporative DED related to meibomian gland dysfunction, topical or oral antibiotics may be considered as well as procedures such as therapeutic meibomian gland expression, thermal pulsation, intraductal probing, and intense pulsed light. [98][99][100][101][102] Notably, risks of dermatologic side effects with intense pulsed light may be greater for darker skin types.…”

Section: Dovepressmentioning

confidence: 99%

Glaucoma and Dry Eye Disease: Opportunity to Assess and Treat

Nijm,

Schweitzer,

Gould Blackmore

2023

OPTH

View full text Add to dashboard Cite

Dry eye disease (DED) has been found to occur at a higher prevalence in individuals with glaucoma than in individuals without glaucoma. The relationship between glaucoma and DED may be, in part, a result of glaucoma therapy. Greater number of antiglaucoma medications used and greater number of antiglaucoma eyedrops instilled per day have been associated with ocular surface disease in patients with glaucoma. Use of antiglaucoma medication has also been associated with higher levels of ocular surface inflammatory markers and ocular surface alterations. There is evidence to suggest that antiglaucoma medications with preservatives and, to some extent, antiglaucoma medication formulations without preservatives may contribute to ocular surface signs and symptoms. Trabeculectomy for glaucoma has also been associated with ocular surface signs related to DED; however, there may be benefits of trabeculectomy and other procedures for glaucoma due to reduced use of antiglaucoma medications. Patients with glaucoma with ocular surface disease have been found to have greater ocular surface symptoms, poorer vision-related quality of life, and poorer antiglaucoma medication adherence compared with patients with glaucoma without ocular surface disease. Because of the potential negative impact of DED on patients with glaucoma, patients with glaucoma may benefit from evaluation for DED. Management of DED in patients with glaucoma may include modifications to antiglaucoma medications and use of treatments for DED.

show abstract

Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease

Cited by 11 publications

References 35 publications

Recent Advances in Nanotechnology for the Treatment of Dry Eye Disease

Recent Advances in Nanotechnology for the Treatment of Dry Eye Disease

Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease

Glaucoma and Dry Eye Disease: Opportunity to Assess and Treat

Contact Info

Product

Resources

About